Skip to main content

CombiMatrix to Receive $2M from US Defense Budget for Bio-Threat Projects

NEW YORK (GenomeWeb News) – CombiMatrix said today that the 2007 Defense Appropriations Bill, recently signed into law, includes two new allocations of $1 million each for the company’s development of microarray technologies for the detection of biological threat agents and infectious pathogens.

According to the company, one of the allocations was specifically granted to address concern over the Eurasian Avian Influenza A Virus, also known as H5N1.

“With this additional capital, our goal is to develop an integrated system that can be used in a laboratory as well as military and civilian environments where early detection can reduce the spread of the disease or the impact of a biothreat attack,” David Danley, director of CombiMatrix’s homeland defense unit, said in a statement.

 

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.